EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synonymous sequence design controls the folding, processing, and activity of the therapeutic protein ADAMTS13

Katarzyna I Jankowska, Upendra K Katneni, Brian C Lin, Hannah M Brenner, Randilu Amarasinghe, Nigam Padhiar, Patrick Dopler, Nobuko Hamasaki-Katagiri, Wells W Wu, Haojie Zhu, Hideki Taguchi, Je-Nie Phue und 11 weitere

Trends in Biotechnology · 2026-10

DOI: 10.1016/j.tibtech.2026.09.003 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Trends in Biotechnology, 2026-10. Verfasst von Katarzyna I Jankowska und 22 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 95 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: US Food and Drug Administration, National Heart Lung and Blood Institute Division of Intramural Research, Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Synonymous recoding is widely used to enhance therapeutic protein expression, yet its broader effects on biogenesis and function remain unclear. We systematically examined how synonymous recoding shapes protein structure, processing, and activity using plasma protease ADAMTS13 (a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13) and its truncated MDTCS (metalloprotease, disintegrin-like, thrombospondin type 1, cysteine-rich, and spacer) variant across cell-free expression, transient transfection, lentiviral delivery, and targeted genomic integration. Wild-type, codon-optimized, and codon-pair-optimized constructs displayed pronounced, system-dependent differences in intracellular proteolysis, secretion, enzymatic performance, and post-translational modifications. Targeted genomic integration produced the highest protein fidelity, whereas transient and lentiviral systems yielded lower extracellular protein levels, particularly for codon-pair-optimized variants. Glycoproteomic analyses revealed distinct glycosylation patterns among synonymous constructs, indicating altered maturation, while Ankyron-based assays detected differences in molecular surface properties of recoding variants. Optimized MDTCS exhibited increased catalytic activity but reduced substrate affinity. These findings demonstrate that synonymous recoding can reshape proteostasis and activity, emphasizing the need for comprehensive evaluation of engineered therapeutic genes beyond yield.

Schlagwörter

Stichwörter der Autor:innen

ADAMTS13AnkyronMDTCScodon optimizationcodon-pair optimizationprotein folding

Autor:innen und Institutionen

  • Division of Hemostasis, Office of Therapeutic Products, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Facility for Biotechnology Resources, Center for Biologics Evaluation & Research, US FDA, Silver Spring, MD, USA.
  • Cell Biology Center, Institute of Integrated Research, Institute of Science Tokyo, Yokohama, Japan.
  • Division of Analytics and Benefit-Risk Assessment, Office of Biostatistics and Pharmacovigilance, Center for Biologics Evaluation and Research, US FDA, Silver Spring, MD, USA.
  • Department of Mathematics, Courant Institute School of Mathematics, Computing, and Data Science, New York University, New York, NY 10012, USA.
  • ProImmune Limited, Unit 1-5 Limbrook, Oasis Park, Stanton Harcourt Road, Eynsham, Oxford OX29 4TP, UK.

Förderung

  • US Food and Drug Administration
  • National Heart Lung and Blood Institute Division of Intramural Research
  • Japan Agency for Medical Research and Development
  • Food and Drug Administration
  • Japan Society for the Promotion of Science
  • JSPS

Zitieren

APA

Jankowska, K. I., Katneni, U. K., Lin, B. C., Brenner, H. M., Amarasinghe, R., Padhiar, N., Dopler, P., Hamasaki-Katagiri, N., Wu, W. W., Zhu, H., Taguchi, H., Phue, J. N., Rahul, P., Smith, S., Santana-Quintero, L., Kimchi, O., Hunt, R. C., Hurst, N. C., Knowlton, E., …, & Kimchi-Sarfaty, C. (2026). Synonymous sequence design controls the folding, processing, and activity of the therapeutic protein ADAMTS13. Trends in Biotechnology. https://doi.org/10.1016/j.tibtech.2026.09.003

Vancouver

Jankowska KI, Katneni UK, Lin BC, Brenner HM, Amarasinghe R, Padhiar N, et al. Synonymous sequence design controls the folding, processing, and activity of the therapeutic protein ADAMTS13. Trends in Biotechnology. 2026. doi:10.1016/j.tibtech.2026.09.003

BibTeX
@article{Jankowska2026,
  author = {Jankowska, Katarzyna I and Katneni, Upendra K and Lin, Brian C and Brenner, Hannah M and Amarasinghe, Randilu and Padhiar, Nigam and Dopler, Patrick and Hamasaki-Katagiri, Nobuko and Wu, Wells W and Zhu, Haojie and Taguchi, Hideki and Phue, Je-Nie and Rahul, Paul and Smith, Sean and Santana-Quintero, Luis and Kimchi, Ofer and Hunt, Ryan C and Hurst, Nicholas C and Knowlton, Emilee and Schwabe, Nikolai F and Komar, Anton A and Fry, Jeremy W and Kimchi-Sarfaty, Chava},
  title = {Synonymous sequence design controls the folding, processing, and activity of the therapeutic protein ADAMTS13},
  journal = {Trends in Biotechnology},
  year = {2026},
  doi = {10.1016/j.tibtech.2026.09.003}
}
Kostenlos starten →